60 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer http://www.zacks.com/stock/news/413860/lillys-cyramza-gets-fda-nod-for-second-line-liver-cancer?cid=CS-ZC-FT-413860 May 14, 2019 - Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
ImmunoGen Plunges as FDA Recommends New Study for Lead Drug http://www.zacks.com/stock/news/415333/immunogen-plunges-as-fda-recommends-new-study-for-lead-drug?cid=CS-ZC-FT-415333 May 16, 2019 - FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/416744/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-416744 May 20, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Company News For May 22, 2019 http://www.zacks.com/stock/news/417942/company-news-for-may-22-2019?cid=CS-ZC--417942 May 22, 2019 - Companies In The News Are: KSS,AZO,HD,MRK
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi http://www.zacks.com/stock/news/420060/incyte-incy-receives-fda-nod-for-label-expansion-of-jakafi?cid=CS-ZC-FT-420060 May 27, 2019 - Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.
3 Drug Stocks That Could Win From Key FDA Approvals in June https://www.fool.com/investing/2019/06/04/3-drug-stocks-that-could-win-from-key-fda-approval.aspx?source=iedfolrf0000001 Jun 04, 2019 - Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.
Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO http://www.zacks.com/stock/news/424416/bristol-myers-bmy-presents-multiple-data-on-opdivo-at-asco?cid=CS-ZC-FT-424416 Jun 04, 2019 - Bristol-Myers (BMY) announces data from multiple studies on immuno-oncology drug, Opdivo, at ASCO.
10 Jaw-Dropping Numbers About Cancer Drug Development -- and What They Mean for Investors https://www.fool.com/investing/2019/06/05/10-jaw-dropping-numbers-about-cancer-drug-developm.aspx?source=iedfolrf0000001 Jun 05, 2019 - There's more good news with the fight against cancer than you might think.
Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication http://www.zacks.com/stock/news/424586/mercks-antibiotic-zerbaxa-gets-fda-nod-for-new-indication?cid=CS-ZC-FT-424586 Jun 04, 2019 - Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
Dow 30 Stock Roundup: UNH to Hike Dividend, MRK Zerbaxa's New Indication Gets FDA Nod http://www.zacks.com/stock/news/426097/dow-30-stock-roundup-unh-to-hike-dividend-mrk-zerbaxas-new-indication-gets-fda-nod?cid=CS-ZC-FT-426097 Jun 07, 2019 - The index enjoyed a week of strong gains after the Fed Chair indicated that a near-term rate cut was increasingly likely.

Pages: 123456

<<<Page 5